




COVID-19 Report

Mathematical Model of COVID-19 Dynamics.
Transmission Scenarios in San Antonio, TX

VOLUME 1

AGGREGATED REPORT

Follow daily updates on Twitter @biomathematicus 

Juan B. Gutierrez, Ph.D.

April 15, 2020 through April 25, 2020

Contents

1	Executive Report	3
1.1	Summary	4
1.2	Impact of Asymptomatic Carriers	4
1.3	Is COVID-19 Just a Flu or a Common Cold?	5
1.4	Description of the Model	6
1.4.1	Model Assumptions	6
1.4.2	Definitions	7
1.4.3	Analysis Protocol	7
1.5	Projections - April 25, 2020	9
1.5.1	Data Sources	12
1.5.2	Heat Maps	13
2	Scientific Background	22
2.1	Authors	23
2.2	Background	23
2.3	Methods	24
2.3.1	Dynamic Model	24
2.3.2	Computation of \mathcal{R}_0	25
2.4	Results	26
2.5	Discussion	27
2.6	Conclusion	27

Chapter 1

Executive Report

1.1 Summary

Coronavirus disease 2019 (COVID-19) is a novel human respiratory disease caused by the SARS-CoV-2 virus. The first cases of COVID-19 surfaced during late December 2019 in Wuhan city, the capital of Hubei province in China. Shortly after, the virus quickly spread to several countries. On January 30th, 2020, The World Health Organization (WHO) declared the virus as a public health emergency of international scope. Forty-one days later, on March 11th, 2020 it was officially declared a global pandemic.

The City of San Antonio had early presence of the pathogen, although it might have not resulted in exposures for the public. San Antonio was a quarantine destination for a number of American evacuees from China and Japan. On February 7th, a plane with 91 quarantined evacuees arrived at Joint Base Lackland in San Antonio (JBSA). On February 17th, two charter flights carrying passengers from Diamond Princess arrived at JBSA. These evacuees remained in quarantine for 14 days from the moment of arrival.

On March 2nd, Mayor Ron Nirenberg issued a Declaration of Public Health Emergency in the City of San Antonio. On April 6th, 2020, Executive Order NW-05 issued by Bexar County Judge Nelson Wolff directed residents of Bexar county to stay at home (“Stay Home Work Safe Measures”). On Friday, April 17th, Executive Order NW-06 was issued to supplement the existing Stay Home, Work Safe measures. These additional measures will remain in place until April 30th, 2020 unless extended, modified or terminated early by the County Judge.

An early response prevented an explosion in the number of cases. Had the Mayor and County Judge not acted early, the crisis would have been significantly larger. The city lockdown has slowed down the progression of the disease. It allowed the health system to prepare for what could be a surge in cases.

The SARS-CoV-2 virus is a highly infectious, relentless pathogen. Once the city lockdown is lifted, a surge in cases is expected shortly after. When the first cases appeared in the US, there was no clarity about the impact of asymptomatic carriers in the dynamics of the disease; the presence of competent asymptomatic carriers makes the disease more difficult to control. Knowledge about this matter is still evolving. Optimal control might be needed to minimize contagion for multiple months, until a vaccine is widely available to the public.

There is agreement between data and the mathematical model in this report. As more data becomes available, the forecast will evolve.

1.2 Impact of Asymptomatic Carriers

The biggest unanswered question regarding COVID-19 is the proportion of the population that is asymptomatic. Estimates of the proportion of asymptomatic COVID-19 carriers vary from:

- 1.1% from the Chinese Center for Disease Control, cross sectional study [52]. The criteria for inclusion was presence of symptoms. The only surprise is that this study found any asymptomatic carrier.

- 17.9% from the Princess cruise ship in Japan [36]. However, the age pyramid of passengers was heavily biased toward > 60 y.o. It does not translate to communities.
- 30.8% from Japanese evacuees from Wuhan [38]. The age pyramid of this group was also tilted toward seniority.
- 50-75% from Vo'Euganeo in Italy. An entire village was tested [12].
- +80% from reanalysis of Chinese data [12].
- 88% in pregnant women in a maternity ward [44].

Having asymptomatic carriers in an epidemic has different degrees of complication. Three scenarios are explored next:

1. Few asymptomatic carriers, e.g. 1 asymptomatic for every 9 symptomatic: Asymptomatic carriers could extend the time to peak. Controlling an outbreak becomes more difficult, but is definitely not a nightmare scenario. Many diseases exhibit this.
2. Half and half (or 20/80 etc.). This is not a good scenario. A high number of asymptomatic carriers accelerates the transmission of a disease, and makes it very hard to contain. This is the only plausible explanation for the unprecedented speed of propagation of COVID-19.
3. Many more asymptomatic than symptomatic, e.g. 80 times more asymptomatic than symptomatic: A recent study reported this scenario [6]. If exposure results in immunity, this scenario is actually less damaging than scenario 2, and might be the most desirable outcome at this point. If many get infected, are not critical cases, and build immunity, this would accelerate the emergence of herd immunity. The disease would fizzle out and disappear.

The least damaging scenario at the moment is 3. In that case, economic activity could resume with a manageable impact. The scenario probably occurring is 2; this case creates a protracted epidemic, with slow build up of herd immunity. Scenario 2 could result in the need of risk mitigation strategies until there is a vaccine. The worst-case scenario would be that: (i) we are in 3, (ii) exposure does not confer immunity, and (iii) a vaccine is elusive as it has been for other coronaviruses that cause the common cold. This scenario would reduce the life expectancy of our entire species. The likelihood of it happening is low at this point.

All hinges on one missing piece of information: The proportion of asymptomatic carriers. Reliable antibody tests are urgently needed.

1.3 Is COVID-19 Just a Flu or a Common Cold?

Much speculation has circulated in the community about the severity of COVID-19. Some compare it to the flu, some to the common cold. SARS-CoV-2 belongs to the family of coronaviruses, some of which cause mild respiratory diseases.

A recent non-scholar report¹ by an experienced emergency medical doctor, indicated that the levels of oxygen in COVID-19 patients can drop substantially below what has been observed for other respiratory conditions, while allowing people to be functional. The atypical COVID-19 silent pneumonia is characterized by air sacs in the lungs not being filled with fluid, but unable to absorb enough oxygen. Afflicted individuals might compensate by involuntarily regulating respiration. By the time individuals seek medical attention, levels of oxygen might be too low, and progression to severity could happen rapidly.

At least one study has attempted to model the epidemiological dynamics of COVID-19 based on other coronaviruses [23]. The premise of this study is that the epidemiological dynamics of the well understood and documented OC43 and HKU1 (coronaviruses that cause mild respiratory disease) can be used to forecast SARS-CoV-19. However, OC43, the most common coronavirus, cannot be used as a basis for SARS-CoV-2 transmission. The spike glycoprotein gene (S-protein) of OC43 has substantial differences with respect to the S-protein of SARS-CoV-2. This has pathogenicity and infectiousness consequences [11], with SARS-CoV-2 having the potential to cause more severe disease through molecular mechanisms. The age-related risk of infection of OC43 vs SARS2 is substantially different [55]. Counting on seasonality is premature, since SARS-CoV-2 might be more resistant to heat than other viruses [41].

In conclusion, COVID-19 is substantially different to other respiratory diseases. Caution must be exercised when extrapolating information and data from other diseases to make COVID-19 predictions.

1.4 Description of the Model

1.4.1 Model Assumptions

The estimates of the model change daily. Single-day reports (identified by a single date on the cover page) produce a single estimate for each scenario. Multi-day reports (identified by a date range on the cover page) show a distribution of estimates and compute a confidence interval for the predictions. Agreement between the data and the model is presented on Figure 1.5 on page 10.

This model is parsimonious, that is, it makes the minimum possible number of assumptions. Table 2.1 on page 26 lists the parameters used in the model. Five parameters related to the biology of the virus were obtained from a comprehensive review of literature. The three fitted parameters are related to the interactions between infected and susceptible subjects. Their value is obtained through parameter calibration.

The estimates in this report are produced with a compartmentalized model based on the work by Aguilar and Gutierrez [2], and Aguilar et al. [1]. The compartments of this model are: susceptible (S), exposed (E), symptomatic (Y), asymptomatic (A), and recovered (R). The acronym for this model is SEYAR.

¹<https://www.nytimes.com/2020/04/20/opinion/coronavirus-testing-pneumonia.html>

1.4.2 Definitions

- Susceptible: Subject who has no immunity to the disease and can be infected.
- Exposed: Subject who has been infected, but is not yet infectious.
- Symptomatic: Subject who shows one of the classic symptoms of COVID-19: fever, cough, general malaise, loss of smell, etc.
- Asymptomatic: Subject who is infectious but has either no awareness of the disease, or who show mild symptoms that permit daily activity and interactions.
- Recovered: Subject who has experienced the disease, is no longer infectious, and is presumed to have immunity.
- Risk (or attack rate or incidence proportion): Number of new cases of disease during a specified time interval.
- Serologic Risk: Risk determined by cross- sectional serological studies, in which antibodies are measured in a population [50].
- Unmitigated Risk: Risk presented to susceptible individuals in absence of mitigation strategies such as social distancing.
- Case Fatality Rate: Proportion of deaths compared to the total number positive cases.

The projected case fatality rate changes depending on the assumptions of the model. The degree of asymptomaticity affects the serological attack rate. Until there are antibody tests with enough sensitivity and specificity, it is not possible to know precisely neither the serologic risk nor the proportion of asymptomatics, and therefore, the range of estimates becomes broad.

As of April 25th, 2020, the level of risk the minimum possible in the City of San Antonio. Mid-point risk means half-way risk between April 25th, and life before the pandemic. Exactly what it means is very difficult to measure, as community interactions happen in a very large number of ways. A supermarket, for example, has today less customers on a regular basis than what they had prior to the pandemic. Mid-point risk would mean the middle point in the number of customer pre-pandemic vs. during the Stay Home, Work Safe measures. Parents of school age children have a different exposure as compared to non-parents, even if they have the same level of mobility. Thus, the measure of risk is simply an average value that represents a very complex constellation of behaviors in the community.

1.4.3 Analysis Protocol

All computations, up to the production of this report, are automated in a single step. Reproducibility of computational results is guaranteed. The model is analyzed according to the following protocol.


- a) Produce an ideal mean response via mathematical modeling.
- b) Get age pyramid by county from US Census data.
- c) Adjust age pyramid to match latest population estimate by county. This is simply a factor F that multiplies the age pyramid, where $F = (\text{latest pop. estimate})/(\text{census data in database})$.
- d) Use age-related probability of complications published from US data and San Antonio
- e) Use age-related probability of symptomatic infection from San Antonio data.
- f) Use percentage population infected by county as reported by NYT at: <https://github.com/nytimes/covid-19-data>
- g) Multiply (a) through (f) and obtain estimates of mild, severe, and critical cases.
- h) Determine correlations between ZIP-level data and cases in San Antonio.
- i) Distribute (g) spatially in San Antonio according to (h).
- j) Extend to the US.
- k) Document and post a pre-print in the medRxiv. Get immediate feedback from the community.
- l) Go to (a) and refine.



This report contains results of mathematical modeling applied to the City of San Antonio. A Data User Agreement between UTSA, San Antonio Metropolitan Health District, and the Southwest Texas Regional Advisory Council (STRAC), facilitated secure data flow across institutional boundaries. Data is currently stored in a secured HIPAA-compliant server at UTSA, used under IRB #20-189. The chapter Technical Report contains the scientific basis for the predictions presented here. See Volume 2 to access county-level predictions of case severity and hospitalizations for every county in the US.


1.5 Projections - April 25, 2020

Assumption: Mobility restrictions lifted on May 1st, 2020. Correction (unwritten): Subtract 1 week from dates to account for delays in reporting. Gray lines represent past 15 model projections; more recent have darker color, current is in red.

	Cases	Date
a1-Current Risk, Active Cases	400	21-Apr-2020
a2-Current Risk, Cumulative Cases	1,800	27-Aug-2020
b1-Mid-Point Risk, Active Cases	1,100	07-Jun-2020
b2-Mid-Point Risk, Cumulative Cases	7,700	27-Aug-2020
c1-Unmitigated Risk, Active Cases	393,100	29-May-2020
c2-Unmitigated Risk, Cumulative Cases	920,000	27-Aug-2020







1.5.1 Data Sources




Figure 1.5-1: partnersSAMHD25-Apr-2020-Sources

1.5.2 Heat Maps




Figure 1.5-2: partnersSAMHD25-Apr-2020-HeatMapAgeRace




Figure 1.5-3: partnersSAMHD25-Apr-2020-HeatMapAgeEthnicity




Figure 1.5-4: partnersSAMHD25-Apr-2020-HeatMapAgeGender




Figure 1.5-5: partnersSAMHD25-Apr-2020-HeatMapAgeFacility




Figure 1.5-6: partnersSAMHD25-Apr-2020-HeatMapAgeDateAdded




Figure 1.5-7: partnersSAMHD25-Apr-2020-HeatMapAgeDateOnset




Figure 1.5-8: partnersSAMHD25-Apr-2020-HeatMapAgeDateAdmission




Figure 1.5-9: partnersSAMHD25-Apr-2020-HeatMapAgeDateOfDeath

Chapter 2

Scientific Background

2.1 Authors

Jacob B. Aguilar¹, Ph.D.,
Jeremy Samuel Faust², MD MS,
Lauren M. Westafer³, DO, MPH, MS,
Yunus Abdussalam, Ph.D.⁴
Bryan Everitt⁵, MD NRP
Juan B. Gutierrez^{6*}, Ph.D.

¹Assistant Professor of Mathematics, Department of Mathematics and Sciences, Saint Leo University.

²Brigham and Women's Hospital, Department of Emergency Medicine
Division of Health Policy and Public Health, Instructor, Harvard Medical School.

³Assistant Professor, Department of Emergency Medicine,
University of Massachusetts Medical School-Baystate
Institute for Healthcare Delivery and Population Science.

⁴Postdoctoral Fellow, University of Texas at San Antonio.

⁵PGY 3, Department of Emergency Medicine, University of Texas Health San Antonio.

⁶Professor of Mathematics, University of Texas at San Antonio.

*To whom correspondence should be addressed: E-mail: juan.gutierrez3@utsa.edu.

2.2 Background

Coronavirus disease 2019 (COVID-19) is a novel human respiratory disease caused by the SARS-CoV-2 virus. The first cases of COVID-19 disease surfaced during late December 2019 in Wuhan city, the capital of Hubei province in China. Shortly after, the virus quickly spread to several countries [16]. On January 30, 2020 The World Health Organization (WHO) declared the virus as a public health emergency of international scope [48]. Forty one days later, on March 11, 2020 it was officially declared to be a global pandemic [49].

Asymptomatic transmission of COVID-19 has been documented [36, 18].

The viral loads of asymptomatic carriers are similar to those in symptomatic carriers [58]. A recent study concluded that asymptomatic and symptomatic carriers may have the same level of infectiousness [34]. An analysis conducted at the Los Alamos National Laboratory estimated a median \mathcal{R}_0 value of 5.7 (95% CI 3.8–8.9) [43]. This is a notable size difference when compared with the initial estimates of the preliminary outbreak dynamics, suggesting \mathcal{R}_0 to be in the interval [0.3, 2.38], see [51, 54, 29, 33]. New estimations of \mathcal{R}_0 are surfacing as more data becomes available, however none of the estimates account for asymptomatic carriers. These findings demand a reassessment of the transmission dynamics of the COVID-19 outbreak that better account for asymptomatic transmission.

The primary aim of this manuscript is to characterize the epidemiological dynamics of SARS-CoV-2 via a compartmentalized model that takes into account asymptomatic sub-populations. The most notable result is that with the most

recent data at the time of publication, COVID-19 has a large basic reproduction number \mathcal{R}_0 which we estimated to fall between 5.5 and 25.4, with a point estimate of 13.2, assuming mean parameters.

2.3 Methods

In this section we summarize the main results, and leave mathematical calculations for the supplementary material. Numerical estimates for the basic reproduction number follow.

2.3.1 Dynamic Model

The *SEYAR* model for the spread of COVID-19 is formulated by decomposing the total host population (N) into the following five epidemiological classes: susceptible human (S), exposed human (E), symptomatic human (Y), asymptomatic human (A), and recovered human (R).




Figure 2.3-1: Schematic diagram of a COVID-19 model including an asymptomatic compartment. The arrows, except the disease-induced death (δ), represent progression from one compartment to the next. Hosts progress through each compartment subject to the rates described below.

The reproduction number \mathcal{R}_0 is a threshold value that characterizes the local asymptotic stability of the underlying dynamical system at a disease-free equilibrium. The reproduction number arising from the dynamical system (Equation 2.2 located in the Supplemental Material) is given by

$$\mathcal{R}_0 = (1 - \alpha) \cdot \beta_Y \cdot \frac{1}{\lambda_{YR} + \delta} + \alpha \cdot \beta_A \cdot \frac{1}{\lambda_{AR}}. \quad (2.1)$$

As the disease-induced death rate δ is of negligible size, the reproduction number \mathcal{R}_0 featured in Equation 2.1 above admits the following natural biological

interpretation:

$$\mathcal{R}_0 \propto \left(\begin{array}{c} \text{probability of becoming} \\ \text{symptomatic upon infection} \end{array} \right) \cdot \left(\begin{array}{c} \text{symptomatic} \\ \text{contact rate} \end{array} \right) \cdot \left(\begin{array}{c} \text{mean symptomatic} \\ \text{infectious period} \end{array} \right) \\ + \left(\begin{array}{c} \text{probability of becoming} \\ \text{asymptomatic upon infection} \end{array} \right) \cdot \left(\begin{array}{c} \text{asymptomatic} \\ \text{contact rate} \end{array} \right) \cdot \left(\begin{array}{c} \text{mean asymptomatic} \\ \text{infectious period} \end{array} \right).$$

A mathematical proof of the calculation yielding the reproduction number \mathcal{R}_0 given by Equation 2.1 is provided in the supplemental material.

The reproduction number is not a biological constant corresponding to a given pathogen [14]. In reality, the values of \mathcal{R}_0 fluctuate with time, and depend on numerous factors. The reproduction number \mathcal{R}_0 provides a way to measure the contagiousness of a disease. It is utilized by public health authorities to gauge the severity of an outbreak. The design and effective implementation of various intervention strategies are guided by estimates of \mathcal{R}_0 . Established outbreaks will fade provided that interventions maintain $\mathcal{R}_0 < 1$.

2.3.2 Computation of \mathcal{R}_0

During the first stages of an epidemic, calculating \mathcal{R}_0 poses significant challenges. Evidence of this difficulty was observed in the 2009 influenza A (H1N1) virus pandemic [37]. Particularly, the COVID-19 pandemic has a different characterization in each country in which it has spread due to differences in surveillance capabilities of public health systems, socioeconomic factors, and environmental conditions.

During the initial growth of an epidemic, Anderson et al. [3] derived the following formula to determine $\mathcal{R}_0 = 1 + \frac{D \ln 2}{t_d}$, where D is the duration of the infectious period, and t_d is the initial doubling time. To find t_d , simply solve for t in $Y = a_0 \cdot (1 + r)^t$, where $Y = 2a_0$, and $r = 23.22\%$ (the rationale for this number is explained below). Thus, $t_d = \ln 2 / \ln(1 + r) \approx 3.32$. The calculated value of the basic reproduction number using the model posed by Anderson is $\mathcal{R}_0 \approx 5.7$, using the mean value of the infectious period reported in Table 2.1. This value should be understood as an underestimation of the true \mathcal{R}_0 because there is no consideration of asymptomatic carriers with this formulation.

A striking characteristic of COVID-19 is the nearly perfect exponential growth reported during the first three weeks of community transmission. Figure 2.3-2 shows the number of cases reported in thirteen countries with universal health care and strong surveillance systems as of March 25, 2020. Ten of these countries are in the European zone, plus Australia, Canada and Japan. An exponential fitting for each country, conducted with the Nelder-Meade simplex algorithm [25], reveals an average coefficient of determination $R^2 = 0.9846 \pm 0.0164$. The average growth rate r in the exponential model $Y = a \cdot (1 + r)^t$, where t is time measured in days, is $r = 23.32\%$, and the average of the initial conditions is $a = 103$ cases. Thus, the average growth of the symptomatic compartment (Y) of COVID-19 during the first three weeks of community transmission in thirteen countries is characterized in average by the equation $Y = 103 \cdot 1.2332^t$, where Y_d represents the distribution of time series of reported cases, and t is time measured in days.

There are well known challenges in attempting to fit an exponential function to epidemiological data [9, 8, 10]. However, given the relatively slow progression of COVID-19, and the protracted infectiousness period, the growth of the symptomatic population can be well characterized by an exponential function for up to three weeks.

The parameters with the greatest uncertainty at the moment of writing are λ_{YR} and λ_{AR} ; hence, we calculated the range of \mathcal{R}_0 using the highest and lowest available values for these parameters. To compare the output of the model to the data from the thirteen countries studied, the growth rate found in the Equation for Y above was superimposed on the model. The initial condition a_0 in the exponential function $Y = a_0 \cdot (1 + r)^t$ was fitted to the dynamical system with the Nelder-Meade simplex algorithm [25]. It is important to emphasize that fitting the initial value simple creates a translation of the curve. It is, therefore, remarkable that the function that describes the average behavior of the first three weeks around the world, presents a nearly perfect fit to the dynamical system using parameters that were measured in multiple settings by different groups.

Table 2.1: Values of parameters used in the average mean response plot. See Appendix for sources.

Parameter	Description	Dimension	Value
FITTED			
β_Y	Effective contact rate from symptomatic to susceptible.	$days^{-1}$	1.30
β_A	Effective contact rate from asymptomatic to susceptible.	$days^{-1}$	1.23
BIOLOGICAL			
γ^{-1}	Mean latent period.	days	5.2
α	Probability of becoming asymptomatic upon infection.	n/a	0.60
λ_{YR}^{-1}	Mean symptomatic infectious period.	$days$	13.5
λ_{AR}^{-1}	Mean asymptomatic infectious period.	$days$	8.33
δ	Disease-induced death rate.	$days^{-1}$	0.026 [45]

2.4 Results

Figure 2.4-3 shows a calculation of the SEYAR model using the parameters reported in Table 2.1. This representation of the progression of the disease must be understood as a theoretical development; in reality, the progression of an epidemic depends on a multitude of factors that necessarily result in deviations from this ideal case.

Changes in behavioral patterns in response to an outbreak have an effect on the propagation of a disease. As people gain awareness of the presence of an infectious disease in their communities, a portion will take measures in order to reduce

their susceptibility. An example of this behavior corresponding to the COVID-19 pandemic is that of social distancing. Indeed, the cancellation of events likely to attract crowds, the closing of schools, and working from home will have a drastic impact on the size of the susceptible population at any given time. Figure 2.4-3 shows time series corresponding to the upper and lower estimations of the basic reproduction number, along with intervention simulations for each scenario. Figure 2.4-4 shows the variation of \mathcal{R}_0 with respect to the symptomatic and asymptomatic mean infectious periods, λ_{YR}^{-1} and λ_{AR}^{-1} .

The size of the COVID-19 reproduction number documented in literature is relatively small. Our estimates indicate that \mathcal{R}_0 is likely to be in the interval from 5.5 to 25.4 with a point estimate of 13.2, when the asymptomatic sub-population is accounted for.

2.5 Discussion

The calculation of \mathcal{R}_0 poses significant challenges during the first stages of any outbreak, including the COVID-19 pandemic. This is due to paucity and timing of surveillance data, different methodological approaches to data collection, and different guidelines for testing. Estimates vary greatly: 0.3 [51], 2.28 [54], 2.38 [29], 3.28 [33], and others. However, none of the previous studies take into consideration the possibility of asymptomatic carriers.

The time series of symptomatic individuals provided by the SEYAR model can inform the likely progression of the disease. The compartment Y must be considered as an upper bound for the progression of the COVID-19 pandemic, that is, what surveillance systems could observe in absence of public health interventions and behavior modification. However, as the COVID-19 pandemic evolves, governments around the world are taking drastic steps to limit community spread. This will necessarily dampen the growth of the disease. The SEYAR model captured faithfully the first stages of the pandemic, and remains a stark reminder of what the cost of inaction could be. It can be used as a tool to explore multiple scenarios corresponding to different interventions.

A scenario where $\mathcal{R}_0 \approx 3$ is remotely plausible requires unrealistic values for the infectious periods. If we consider the median of the other parameters to be correct, then the mean infectious periods should be approximately 4.4 days. If we reduced the probability of becoming asymptomatic upon infection to $\alpha = 0.3$, then the mean infectious periods would be 3.1 days. These infectious periods are not consistent with evidence. The necessary conclusion is that via a computational *reductio ad absurdum*, in tandem with the information we have today, \mathcal{R}_0 cannot be near 3.

2.6 Conclusion

It is unlikely that a pathogen that blankets the planet in three months can have a basic reproduction number in the vicinity of 3, as reported in the literature [42, 32, 35, 7, 56, 19]. In juxtaposition to the SARS-CoV epidemic of 2003 [4],

where only symptomatic individuals were capable of transmitting the disease, asymptomatic carriers of the SARS-CoV-2 virus may be capable of the same degree of transmission as symptomatic individuals [58]. In a public health context, the silent threat posed by the presence of asymptomatic and other undocumented carriers in the population renders the COVID-19 pandemic far more difficult to control. SARS-CoV-2 is evidently among the more contagious pathogens known, a phenomenon most likely driven by the asymptomatic sub-population.

The value of \mathcal{R}_0 must be understood as a threshold parameter that can be utilized to characterize disease spread. The estimations of \mathcal{R}_0 are expected to vary substantially per locality depending on how public health officials communicate the risk to the general public, general beliefs and (dis)information available to the population, and other socioeconomic and environmental factors affecting contact rates. Our goal with this investigation was to develop the SEYAR mean field estimate, which can be applied to different locations to provide a measure of the potential impact of the disease.

This study shows that asymptomatic individuals are major drivers for the growth of the COVID-19 pandemic. The value of \mathcal{R}_0 we calculated is at least double and up to one order of magnitude larger than the estimates that have been communicated in the literature and to policymakers up to this point.

Appendix

Table 2.2: Latent period

Parameter	Dimension	Biological	Computational	Source
γ^{-1}	days	5.1(4.5, 5.8)	n/a	[27]
		5.2(4.1, 7)	n/a	[28]
		6.4(5.6, 7.7)	n/a	[5]
		5.2(1.8, 12.4)	n/a	[53]
		5.2(4.2, 6)	n/a	[26]
		3.9	n/a	[22]
		5(4.2, 6.0)	n/a	[31] ¹
		5.6(5, 6.3)	n/a	[31] ²
		n/a	4.2(3.5, 5.1)	[43] ⁶
		n/a	1.25	[20]
		n/a	3.68(3.48, 3.90)	[30] ³
		n/a	3.62(3.44, 3.87)	[30] ⁴
		n/a	3.43(3.30, 3.63)	[30] ⁵
Mean	5.2	3.2		
Variance	0.5	1.3		

The latent period is defined to be the number of days elapsed between exposure to the pathogen and when symptoms are manifested. This parameter is also referred to as the mean incubation period in the literature. Quantities are listed as values, ranges or Median(95% CIs).

- (1) This data corresponds to the case of excluding Wuhan.
- (2) This data corresponds to the case of including Wuhan.
- (3) This estimate corresponds to the best-fit model posterior estimates of key epidemiological parameters for simulation during January 10-23, 2020.
- (4) This estimate corresponds to the best-fit model posterior estimates of key epidemiological parameters for simulation during January 24-February 3, 2020.
- (5) This estimate corresponds to the best-fit model posterior estimates of key epidemiological parameters for simulation during January 24-February 8, 2020.
- (6) This estimate was obtained utilizing a uniform distribution from 2.2 to 6 days.

Table 2.3: Asymptomatic Proportion

Parameter	Dimension	Biological	Computational	Source
α	n/a	17.9%(15.5%, 20.2%)	n/a	[36]
		33.3%	n/a	[15] ¹
		[50%, 75%]	n/a	[12]
		80%	n/a	[40]
		n/a	41.6%(16.7%, 66.7%)	[38] ²
		[80%, 95%]	n/a	[39] ¹
		n/a	86%(82%, 90%)	[30]
		78%	n/a	[13]
		Mean	60%	60%
Variance	10%	10%		

The probability of becoming asymptomatic upon infection is obtained by the proportion of asymptomatic infections in a given population and is utilized as a transmission factor accounting for the asymptomatic sub-population. Quantities are listed as values, ranges or Median(95% CIs).

- (1) This percentage was assumed.
- (2) A Bayes theorem was utilized to obtain this estimation.

Table 2.4: Asymptomatic Infectious Period

Parameter	Dimension	Biological	Computational	Source
λ_{AR}^{-1}	days	8.33	n/a	[47] ¹
		n/a	3.45(3.24, 3.70)	[30] ²

The asymptomatic infectious period is defined to be the number of days an individual who never develops symptoms exhibits viral shedding. For the asymptomatic infectious period we assumed viral shedding was synonymous with transmissibility. Quantities are listed as values, ranges or Median(95% CIs).

- (1) This quantity was estimated by taking the average number of days for which viral RNA was detected via swab one day prior to the limit of quantification.
- (2) This estimate corresponds to the best-fit model posterior estimates of key epidemiological parameters for simulation during January 10-23, 2020.

Table 2.5: Symptomatic Infectious Period

Parameter	Dimension	Biological	Computational	Source
λ_{YR}^{-1}	days	[10, 11]	n/a	[47] ¹
		n/a	2.9	[24]
		20(17, 24)	n/a	[57] ²
		10	n/a	[17]
		n/a	3.47(3.26, 3.67)	[30] ³
		n/a	3.15(2.62, 3.71)	[30] ⁴
		n/a	3.32(2.92, 4.04)	[30] ⁵
		n/a	[4, 14]	[43] ⁶
		Mean	13.5	4.4
Variance	31.8	6.7		

The symptomatic infectious period is the number of days an individual who develops COVID-19 symptoms exhibits viral shedding. For the symptomatic infectious period we assumed viral shedding was synonymous with transmissibility. Quantities are listed as values, ranges or Median(95% CIs).

- (1) This assumption is based on the finding that sputum viral loads showed a late and high peak around days 10 to 11.
- (2) In this finding, the median duration of viral shedding was 20 days with interquartile range of (17, 24).
- (3) This estimate corresponds to the best-fit model posterior estimates of key epidemiological parameters for simulation during January 10-23, 2020.
- (4) This estimate corresponds to the best-fit model posterior estimates of key epidemiological parameters for simulation during January 24-February 3, 2020.
- (5) This estimate corresponds to the best-fit model posterior estimates of key epidemiological parameters for simulation during January 24-February 8, 2020.
- (6) This interval corresponds to the range of a uniform distribution.

Equation 2.2 is a *SEYAR* dynamical system describing the dynamics of COVID-19 transmission in a human population. The dynamical system given by Equation 2.2 was computed with the values appearing in Table 1.

$$\begin{cases} \dot{S} = -(\beta_Y \frac{Y}{N} + \beta_A \frac{A}{N}) S, \\ \dot{E} = (\beta_Y \frac{Y}{N} + \beta_A \frac{A}{N}) S - \gamma E, \\ \dot{Y} = \gamma(1 - \alpha)E - (\delta + \lambda_{YR}) Y, \\ \dot{A} = \gamma\alpha E - \lambda_{AR} A, \\ \dot{R} = \lambda_{AR} A + \lambda_{YR} Y, \end{cases} \quad (2.2)$$

where, $N = S + E + Y + A + R$. A slightly generalized model is covered below in which the model utilized in this manuscript is a specific case. The generalized *SEYAR* dynamical system in Equation 2.3 which falls into the class of models covered by Aguilar and Gutierrez (2020) [2], (see Figure 2.6-5) is given by the following equations:

$$\begin{cases} \dot{S} = \Lambda + \lambda_{RS}R - (\beta_Y \frac{Y}{N} + \beta_A \frac{A}{N} + \xi) S, \\ \dot{E} = (\beta_Y \frac{Y}{N} + \beta_A \frac{A}{N}) S - (\gamma + \xi) E, \\ \dot{Y} = \gamma(1 - \alpha)E - (\xi + \delta + \lambda_{YR}) Y + \lambda_{AY} A, \\ \dot{A} = \gamma\alpha E - (\lambda_{AR} + \lambda_{AY} + \xi) A, \\ \dot{R} = \lambda_{AR} A + \lambda_{YR} Y - (\lambda_{RS} + \xi) R, \end{cases} \quad (2.3)$$

where, $N = S + E + Y + A + R$. The demographic parameters Λ and ξ denote the human recruitment and mortality rates, respectively. While λ_{AY} and λ_{RS} are the asymptomatic to symptomatic transition and relapse rates, respectively.

It is worth mentioning that for a basic *SEIR* model, where there is only one infected compartment, the progression rate from the susceptible to the exposed class λ_{SE} is equal to the product of the effective contact rate β and the proportion of infected individuals $\frac{I}{N}$, so that

$$\lambda_{SE} = \beta \frac{I}{N}.$$

In our model, we decompose the infected compartment into symptomatic and asymptomatic sub-compartments. Due to this decomposition, the progression rate is given by the weighted sum

$$\lambda_{SE} = \left(\beta_Y \frac{Y}{N} + \beta_A \frac{A}{N} \right).$$

Disease-Free Equilibrium (DFE) points are solutions of a dynamical system corresponding to the case where no disease is present in the population.

Lemma 1. (*Reproduction Number for the SEYAR COVID-19 Model*). Define the following quantity

$$\mathcal{R}_0 := \frac{\gamma}{\gamma + \xi} \left(\frac{\beta_Y}{\delta + \lambda_{YR} + \xi} \left(\frac{\alpha \lambda_{AY}}{\lambda_{AR} + \lambda_{AY} + \xi} - (\alpha - 1) \right) + \frac{\alpha \beta_A}{\lambda_{AR} + \lambda_{AY} + \xi} \right). \quad (2.4)$$

Then, the DFE \mathbf{w}^* for the SEYAR model in Equation 2.3 is locally asymptotically stable provided that $\mathcal{R}_0 < 1$ and unstable if $\mathcal{R}_0 > 1$.

Proof. We order the compartments so that the first four correspond to the infected sub-populations and denote $\mathbf{w} = (E, Y, A, R, S)^T$. The corresponding DFE is

$$\mathbf{w}^* = \left(0, 0, 0, 0, \frac{\Lambda}{\xi} \right)^T.$$

Utilizing the next generation method developed by Van den Driessche and Watmough [46], system in Equation 2.3 is rewritten in the following form

$$\dot{\mathbf{w}} = \Phi(\mathbf{w}) = \mathcal{F}(\mathbf{w}) - \mathcal{V}(\mathbf{w}),$$

where $\mathcal{F} := (\mathcal{F}_1, \dots, \mathcal{F}_5)^T$ and $\mathcal{V} := (\mathcal{V}_1, \dots, \mathcal{V}_5)^T$, or more explicitly

$$\begin{pmatrix} \dot{E} \\ \dot{Y} \\ \dot{A} \\ \dot{R} \\ \dot{S} \end{pmatrix} = \begin{pmatrix} (\beta_Y \frac{Y}{N} + \beta_A \frac{A}{N}) S \\ 0 \\ 0 \\ 0 \\ 0 \end{pmatrix} - \begin{pmatrix} (\gamma + \xi) E \\ -\gamma(1 - \alpha) E + (\xi + \delta + \lambda_{YR}) Y - \lambda_{AY} A \\ -\gamma \alpha E + (\lambda_{AR} + \lambda_{AY} + \xi) A \\ -\lambda_{AR} A - \lambda_{YR} Y + (\lambda_{RS} + \xi) R \\ -\Lambda - \lambda_{RS} R + (\beta_Y \frac{Y}{N} + \beta_A \frac{A}{N} + \xi) S \end{pmatrix}.$$

The matrix \mathcal{V} admits the decomposition $\mathcal{V} = \mathcal{V}^- - \mathcal{V}^+$, where the component-wise definition is inherited. In a biological context, \mathcal{F}_i is the rate of appearance of new infections in compartment i , \mathcal{V}_i^+ stands for the rate of transfer of individuals into compartment i by any other means and \mathcal{V}_i^- is the rate of transfer of individuals out of compartment i . Now, let F and V be the following sub-matrices of the Jacobian of the above system, evaluated at the solution \mathbf{w}^*

$$F = \left(\frac{\partial \mathcal{F}_i}{\partial x_j} \Big|_{\mathbf{w}^*} \right)_{1 \leq i, j \leq 3} = \begin{pmatrix} 0 & \beta_Y & \beta_A \\ 0 & 0 & 0 \\ 0 & 0 & 0 \end{pmatrix}$$

and

$$V = \left(\frac{\partial \mathcal{V}_i}{\partial x_j} \Big|_{\mathbf{w}^*} \right)_{1 \leq i, j \leq 3} = \begin{pmatrix} (\gamma + \xi) & 0 & 0 \\ \gamma(\alpha - 1) & (\xi + \delta + \lambda_{YR}) & -\lambda_{AY} \\ -\gamma\alpha & 0 & (\lambda_{AR} + \lambda_{AY} + \xi) \end{pmatrix}.$$

A direct calculation shows that

$$V^{-1} = \begin{pmatrix} -\frac{\gamma((\alpha-1)(\lambda_{AR}+\xi)-\lambda_{AY})}{(\gamma+\xi)(\xi+\delta+\lambda_{YR})(\xi+\lambda_{AY}+\lambda_{AR})} & 0 & 0 \\ (\xi+\delta+\lambda_{YR})^{-1} & \lambda_{AY}((\xi+\delta+\lambda_{YR})(\xi+\lambda_{AY}+\lambda_{AR}))^{-1} & 0 \\ \frac{\gamma\alpha((\gamma+\xi)(\lambda_{AR}+\lambda_{AY}+\xi))^{-1}}{0} & 0 & (\lambda_{AR}+\lambda_{AY}+\xi)^{-1} \end{pmatrix}$$

and FV^{-1} is given by the following matrix

$$\begin{pmatrix} \frac{\gamma}{(\gamma+\xi)(\lambda_{AR}+\lambda_{AY}+\xi)} \left(-\frac{\beta_Y((\alpha-1)(\lambda_{AR}+\xi)-\lambda_{AY})}{\delta+\lambda_{YR}+\xi} + \beta_A\alpha \right) & \beta_Y(\delta+\lambda_{YR}+\xi)^{-1} & \frac{1}{\lambda_{AR}+\lambda_{AY}+\xi} \left(\frac{\beta_Y\lambda_{AY}}{\delta+\lambda_{YR}+\xi} + \beta_A \right) \\ 0 & 0 & 0 \\ 0 & 0 & 0 \end{pmatrix}.$$

Let \mathcal{I} denote the 3×3 identity matrix, so that the characteristic polynomial $P(\lambda)$ of the matrix FV^{-1} is given by

$$\begin{aligned} P(\lambda) &= \det(FV^{-1} - \lambda\mathcal{I}), \\ &= \lambda^2 \left(\lambda - \left(\frac{\gamma\beta_Y}{(\gamma+\xi)(\delta+\lambda_{YR}+\xi)} \left(\frac{\alpha\lambda_{AY}}{\lambda_{AR}+\lambda_{AY}+\xi} + 1 - \alpha \right) + \frac{\gamma\alpha\beta_A}{(\gamma+\xi)(\lambda_{AR}+\lambda_{AY}+\xi)} \right) \right). \end{aligned}$$

The solution set $\{\lambda_i\}_{1 \leq i \leq 3}$ is given by

$$\left\{ 0, 0, \frac{\gamma\beta_Y}{(\gamma+\xi)(\delta+\lambda_{YR}+\xi)} \left(\frac{\alpha\lambda_{AY}}{\lambda_{AR}+\lambda_{AY}+\xi} + 1 - \alpha \right) + \frac{\gamma\alpha\beta_A}{(\gamma+\xi)(\lambda_{AR}+\lambda_{AY}+\xi)} \right\}.$$

Therefore, the reproduction number for the *SEYAR* model in Equation 2.3 is given by

$$\begin{aligned} \mathcal{R}_0 &:= \rho(FV^{-1}), \\ &= \max_{1 \leq i \leq 3} \{\lambda_i\}, \\ &= \frac{\gamma\beta_Y}{(\gamma+\xi)(\delta+\lambda_{YR}+\xi)} \left(\frac{\alpha\lambda_{AY}}{\lambda_{AR}+\lambda_{AY}+\xi} + 1 - \alpha \right) + \frac{\gamma\alpha\beta_A}{(\gamma+\xi)(\lambda_{AR}+\lambda_{AY}+\xi)}, \\ &= \frac{\gamma}{\gamma+\xi} \left(\frac{\beta_Y}{\delta+\lambda_{YR}+\xi} \left(\frac{\alpha\lambda_{AY}}{\lambda_{AR}+\lambda_{AY}+\xi} - (\alpha-1) \right) + \frac{\alpha\beta_A}{\lambda_{AR}+\lambda_{AY}+\xi} \right). \end{aligned}$$

The proof of the lemma regarding the local asymptotic stability of the DFE \mathbf{w}^* corresponding to the *SEYAR* model in Equation 2.3 is now complete after invoking Theorem 2 reported by Van den Driessche and Watmough (2002) [46]. \square

Equation 1 in the manuscript corresponds to the DFE solution given by $\mathbf{v}^* = (0, 0, 0, 0, S_0)^T$ and the absence of demographic parameters and asymptomatic to symptomatic transition rate. It can alternatively be obtained by letting $\xi = \lambda_{AY} = 0$ in Equation 2.4. A verification of the calculation yielding the reproduction number \mathcal{R}_0 given by Equation 2.4 is provided in the electronic supplementary material.

The reproduction number \mathcal{R}_0 shown in Equation 1 in the manuscript arising from our model admits a natural biological interpretation. To guide this discussion, it is pertinent to refer to the original epidemic model proposed by W. O. Kermack and A. G. McKendrick in 1927 [21], see Figure 2.6-6 below. The corresponding dynamical system is given by

$$\begin{cases} \dot{S} = -\beta \frac{I}{N} S, \\ \dot{I} = \beta \frac{I}{N} S - \omega I, \\ \dot{R} = \omega I. \end{cases} \quad (2.5)$$

Epidemiologically speaking, the basic reproduction number is the average number of secondary infections generated by a single infection in a completely susceptible population. It is proportional to the product of infection/contact (a), contact/time (b) and time/infection (c). The quantity a is the infection probability between susceptible and infectious individuals, b is the mean contact rate between susceptible and infectious individuals and c is the mean duration of the infectious period.

The case of an increasing infected sub-population corresponds to the occurrence of an epidemic. This happens provided that $\dot{I} = \beta \frac{I}{N} S - \omega I > 0$ or $\frac{\beta}{\omega} \frac{S}{N} > 1$. Under the assumption that in the beginning of an epidemic, virtually the total population is susceptible, that is $\frac{S}{N} \approx 1$. As a result, we arrive at the following equivalent condition

$$\mathcal{R}_0 := \frac{\beta}{\omega} > 1.$$

The parameter β in Figure 2.6-6 is equal to ab and ω is equal to c^{-1} . This combination of parameters stands to reason as it is a ratio of the effective contact rate β and the mean infectious period ω^{-1} .

Since the disease-induced death rate $\delta \approx 0$, the reproduction number in Equation 2 in the manuscript for our model has a similar natural interpretation as the sum of ratios consisting of the effective contact rates β_Y, β_A and mean infectious periods $\lambda_{YR}^{-1}, \lambda_{AR}^{-1}$ for the symptomatic and asymptomatic sub-populations, weighted with the probabilities of becoming symptomatic $(1 - \alpha)$ or asymptomatic α upon infection.

The effective reproduction number $\mathcal{R}_0(t)$ takes into consideration the susceptibility of the population,

$$\mathcal{R}_0(t) := \frac{\mathcal{R}_0}{N(t)} S(t). \quad (2.6)$$

It is defined to be the average number of secondary cases generated by a typical case. A decrease in the susceptible population overtime will cause a corresponding decrease in the values of the reproduction number. It directly follows by Equation 2.6 that $\mathcal{R}_0(0) = \mathcal{R}_0$, as initially the total human population is assumed to be

susceptible. The plot of $\mathcal{R}_0(t)$ is similar to the plot of the susceptible portion, featured in Figure 3 in the manuscript. This is reasonable since Equation 2.6 implies that $\mathcal{R}_0(t)$ is proportional to $S(t)$. Since $\delta \approx 0$, the total population $N(t)$ varies little within a tight envelope around the initial susceptible population $S(0)$. This is easily observable upon inspection of the dynamical system given by Equation 1 in the manuscript, as it is clear that

$$N(t) = S(0) - \delta \int_0^t Y(\zeta) d\zeta.$$




Figure 2.3-2: First three weeks (or less) of data for thirteen countries with COVID-19 cases and strong surveillance systems for communicable diseases.




Figure 2.4-3: Numerical implementation of a SEYAR model with the parameters listed on Table 2.1. The left-most panel shows the time series corresponding to a point estimate of $\mathcal{R}_0 = 13.2$. The center panel shows a times series of the symptomatic compartment; the red dots represent the exponential function whose parameters are the average of the thirteen countries studied. The right-most panel shows a simulation representing the effect of limiting contact between the susceptible and infected populations.




Figure 2.4-4: Heat map showing the variation of the basic reproduction number \mathcal{R}_0 with respect to the asymptomatic and symptomatic infectious periods λ_{AR}^{-1} and λ_{YR}^{-1} , respectively.




Figure 2.6-5: This figure is a schematic diagram of a generalized COVID-19 model including an asymptomatic compartment. The longer arrows represent progression from one compartment to the next. Hosts enter the susceptible compartment either through birth or migration and then progress through each additional compartment subject to the rates described above.




Figure 2.6-6: This figure is a schematic diagram of a SIR model consisting of three compartments, namely: susceptible (S), infected (I) and recovered (R). Humans progress through each compartment subject to the rates described above.

Bibliography

- [1] J. B. Aguilar, J. S. Faust, L. M. Westafer, and J. B. Gutierrez. Investigating the impact of asymptomatic carriers on covid-19 transmission. *medRxiv*, 2020.
- [2] J. B. Aguilar and J. B. Gutierrez. An epidemiological model of malaria accounting for asymptomatic carriers. *Bulletin of Mathematical Biology*, 82(3):42, 2020.
- [3] R. Anderson, G. Medley, R. May, and A. Johnson. A preliminary study of the transmission dynamics of the human immunodeficiency virus (hiv), the causative agent of aids. *Mathematical Medicine and Biology: a Journal of the IMA*, 3(4):229–263, 1986.
- [4] R. M. Anderson, C. Fraser, A. C. Ghani, C. A. Donnelly, S. Riley, N. M. Ferguson, G. M. Leung, T. H. Lam, and A. J. Hedley. Epidemiology, transmission dynamics and control of sars: the 2002–2003 epidemic. *Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences*, 359(1447):1091–1105, 2004.
- [5] J. A. Backer, D. Klinkenberg, and J. Wallinga. Incubation period of 2019 novel coronavirus (2019-ncov) infections among travellers from wuhan, china, 20–28 january 2020. *Eurosurveillance*, 25(5), 2020.
- [6] E. Bendavid, B. Mulaney, N. Sood, S. Shah, E. Ling, R. Bromley-Dulfano, C. Lai, Z. Weissberg, R. Saavedra, J. Tedrow, et al. Covid-19 antibody seroprevalence in santa clara county, california. *medRxiv*, 2020.
- [7] Z. Cao, Q. Zhang, X. Lu, D. Pfeiffer, Z. Jia, H. Song, and D. D. Zeng. Estimating the effective reproduction number of the 2019-ncov in china. *medRxiv*, 2020.
- [8] G. Chowell, L. Sattenspiel, S. Bansal, and C. Viboud. Early sub-exponential epidemic growth: Simple models, nonlinear incidence rates, and additional mechanisms: Reply to comments on” mathematical models to characterize early epidemic growth: A review”. *Physics of life reviews*, 18:114, 2016.
- [9] G. Chowell and C. Viboud. Is it growing exponentially fast?—impact of assuming exponential growth for characterizing and forecasting epidemics with initial near-exponential growth dynamics. *Infectious disease modelling*, 1(1):71–78, 2016.

- [10] G. Chowell, C. Viboud, L. Simonsen, and S. M. Moghadas. Characterizing the reproduction number of epidemics with early subexponential growth dynamics. *Journal of The Royal Society Interface*, 13(123):20160659, 2016.
- [11] B. Coutard, C. Valle, X. de Lamballerie, B. Canard, N. Seidah, and E. Decroly. The spike glycoprotein of the new coronavirus 2019-ncov contains a furin-like cleavage site absent in cov of the same clade. *Antiviral research*, 176:104742, 2020.
- [12] M. Day. Covid-19: four fifths of cases are asymptomatic, china figures indicate, 2020.
- [13] M. Day. Covid-19: Four fifths of cases are asymptomatic, china figures indicate, 2020.
- [14] P. L. Delamater, E. J. Street, T. F. Leslie, Y. T. Yang, and K. H. Jacobsen. Complexity of the basic reproduction number (r_0). *Emerging infectious diseases*, 25(1):1, 2019.
- [15] N. Ferguson, D. Laydon, G. Nedjati-Gilani, et al. Impact of non-pharmaceutical interventions (npis) to reduce covid-19 mortality and health-care demand. imperial college covid-19 response team, 2020.
- [16] W.-j. Guan, Z.-y. Ni, Y. Hu, W.-h. Liang, C.-q. Ou, J.-x. He, L. Liu, H. Shan, C.-l. Lei, D. S. Hui, et al. Clinical characteristics of coronavirus disease 2019 in china. *New England Journal of Medicine*, 2020.
- [17] X. He, E. H. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y. Guan, X. Tan, et al. Temporal dynamics in viral shedding and transmissibility of covid-19. *medRxiv*, 2020.
- [18] Z. Hu, C. Song, C. Xu, G. Jin, Y. Chen, X. Xu, H. Ma, W. Chen, Y. Lin, Y. Zheng, et al. Clinical characteristics of 24 asymptomatic infections with covid-19 screened among close contacts in nanjing, china. *Science China Life Sciences*, pages 1–6, 2020.
- [19] N. Imai, A. Cori, I. Dorigatti, M. Baguelin, C. A. Donnelly, S. Riley, and N. M. Ferguson. Report 3: transmissibility of 2019-ncov. *Reference Source*, 2020.
- [20] E. Java, S. Fox, and L. A. M. Meyers. Probability of current covid-19 outbreaks in all us counties. *medRxiv*, 2020.
- [21] W. Kermack and A. Mckendrick. A contribution to the mathematical theory of epidemics. *Proc Roy Soc London*, A 115:700–721, 1927.
- [22] M. Ki et al. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-ncov) disease in republic of korea. *Epidemiology and health*, page e2020007, 2020.

- [23] S. M. Kissler, C. Tedijanto, E. Goldstein, Y. H. Grad, and M. Lipsitch. Projecting the transmission dynamics of sars-cov-2 through the postpandemic period. *Science*, 2020.
- [24] A. J. Kucharski, T. W. Russell, C. Diamond, Y. Liu, J. Edmunds, S. Funk, R. M. Eggo, F. Sun, M. Jit, J. D. Munday, et al. Early dynamics of transmission and control of covid-19: a mathematical modelling study. *The lancet infectious diseases*, 2020.
- [25] J. C. Lagarias, J. A. Reeds, M. H. Wright, and P. E. Wright. Convergence properties of the nelder–mead simplex method in low dimensions. *SIAM Journal on optimization*, 9(1):112–147, 1998.
- [26] S. A. Lauer, K. H. Grantz, Q. Bi, F. K. Jones, Q. Zheng, H. Meredith, A. S. Azman, N. G. Reich, and J. Lessler. The incubation period of 2019-ncov from publicly reported confirmed cases: estimation and application. *medRxiv*, 2020.
- [27] S. A. Lauer, K. H. Grantz, Q. Bi, F. K. Jones, Q. Zheng, H. R. Meredith, A. S. Azman, N. G. Reich, and J. Lessler. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Annals of Internal Medicine*, 03 2020.
- [28] Q. Li, X. Guan, P. Wu, X. Wang, L. Zhou, Y. Tong, R. Ren, K. S. Leung, E. H. Lau, J. Y. Wong, et al. Early transmission dynamics in wuhan, china, of novel coronavirus–infected pneumonia. *New England Journal of Medicine*, 2020.
- [29] R. Li, S. Pei, B. Chen, Y. Song, T. Zhang, W. Yang, and J. Shaman. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (covid-19). *medRxiv*, 2020.
- [30] R. Li, S. Pei, B. Chen, Y. Song, T. Zhang, W. Yang, and J. Shaman. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (sars-cov2). *Science*, 2020.
- [31] N. M. Linton, T. Kobayashi, Y. Yang, K. Hayashi, A. R. Akhmetzhanov, S.-m. Jung, B. Yuan, R. Kinoshita, and H. Nishiura. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data. *Journal of clinical medicine*, 9(2):538, 2020.
- [32] T. Liu, J. Hu, M. Kang, L. Lin, H. Zhong, J. Xiao, G. He, T. Song, Q. Huang, Z. Rong, et al. Transmission dynamics of 2019 novel coronavirus (2019-ncov). *SSRN*, 2020.
- [33] Y. Liu, A. A. Gayle, A. Wilder-Smith, and J. Rocklöv. The reproductive number of covid-19 is higher compared to sars coronavirus. *Journal of travel medicine*, 2020.

- [34] C. R. MacIntyre. Global spread of covid-19 and pandemic potential. *Global Biosecurity*, 1(3), 2020.
- [35] M. Majumder and K. D. Mandl. Early transmissibility assessment of a novel coronavirus in wuhan, china. *China (January 23, 2020)*, 2020.
- [36] K. Mizumoto, K. Kagaya, A. Zarebski, and G. Chowell. Estimating the asymptomatic proportion of coronavirus disease 2019 (covid-19) cases on board the diamond princess cruise ship, yokohama, japan, 2020. *Eurosurveillance*, 25(10):2000180, 2020.
- [37] H. Nishiura, G. Chowell, M. Safan, and C. Castillo-Chavez. Pros and cons of estimating the reproduction number from early epidemic growth rate of influenza a (h1n1) 2009. *Theoretical Biology and Medical Modelling*, 7(1):1, 2010.
- [38] H. Nishiura, T. Kobayashi, T. Miyama, A. Suzuki, S. Jung, K. Hayashi, R. Kinoshita, Y. Yang, B. Yuan, A. R. Akhmetzhanov, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (covid-19). *medRxiv*, 2020.
- [39] H. Nishiura, T. Kobayashi, Y. Yang, K. Hayashi, T. Miyama, R. Kinoshita, N. M. Linton, S.-m. Jung, B. Yuan, A. Suzuki, et al. The rate of under-ascertainment of novel coronavirus (2019-ncov) infection: Estimation using japanese passengers data on evacuation flights, 2020.
- [40] W. H. Organization et al. Coronavirus disease 2019 (covid-19): situation report, 46. 2020.
- [41] B. Pastorino, F. Touret, M. Gilles, X. de Lamballerie, and R. N. Charrel. Evaluation of heating and chemical protocols for inactivating sars-cov-2. *bioRxiv*, 2020.
- [42] J. M. Read, J. R. Bridgen, D. A. Cummings, A. Ho, and C. P. Jewell. Novel coronavirus 2019-ncov: early estimation of epidemiological parameters and epidemic predictions. *medRxiv*, 2020.
- [43] S. Sanche, Y. Lin, C. Xu, E. Romero-Severson, N. Hengartner, and R. Ke. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. *Emerging infectious diseases*, 26(7), 2020.
- [44] D. Sutton, K. Fuchs, M. D’Alton, and D. Goffman. Universal screening for sars-cov-2 in women admitted for delivery. *New England Journal of Medicine*, 2020.
- [45] C. C.-. R. Team. Response team. severe outcomes among patients with coronavirus disease 2019 (covid-19)—united states, february 12–march 16, 2020. *MMWR Morb Mortal Wkly Rep*, 69(12):343–346, 2020.

- [46] P. Van den Driessche and J. Watmough. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. *Mathematical biosciences*, 180(1):29–48, 2002.
- [47] R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M. A. Müller, D. Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, et al. Virological assessment of hospitalized patients with covid-2019. *Nature*, pages 1–10, 2020.
- [48] World Health Organization. Coronavirus disease (covid-19) outbreak.
- [49] World Health Organization. who director-general’s opening remarks at the media briefing on covid-19 - 11 march 2020.
- [50] J. T. Wu, A. Ho, E. S. Ma, C. K. Lee, D. K. Chu, P.-L. Ho, I. F. Hung, L. M. Ho, C. K. Lin, T. Tsang, et al. Estimating infection attack rates and severity in real time during an influenza pandemic: analysis of serial cross-sectional serologic surveillance data. *PLoS medicine*, 8(10), 2011.
- [51] P. Wu, X. Hao, E. H. Lau, J. Y. Wong, K. S. Leung, J. T. Wu, B. J. Cowling, and G. M. Leung. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in wuhan, china, as at 22 january 2020. *Eurosurveillance*, 25(3), 2020.
- [52] Z. Wu and J. M. McGoogan. Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention. *Jama*, 2020.
- [53] J. Zhang, M. Litvinova, W. Wang, Y. Wang, X. Deng, X. Chen, M. Li, W. Zheng, L. Yi, X. Chen, et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside hubei province, china: a descriptive and modelling study. *The Lancet Infectious Diseases*, 2020.
- [54] S. Zhang, M. Diao, W. Yu, L. Pei, Z. Lin, and D. Chen. Estimation of the reproductive number of novel coronavirus (covid-19) and the probable outbreak size on the diamond princess cruise ship: A data-driven analysis. *International Journal of Infectious Diseases*, 2020.
- [55] S.-f. Zhang, J.-l. Tuo, X.-b. Huang, X. Zhu, D.-m. Zhang, K. Zhou, L. Yuan, H.-j. Luo, B.-j. Zheng, K.-y. Yuen, et al. Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of hcov-oc43 during 2010-2015 in guangzhou. *PloS one*, 13(1), 2018.
- [56] S. Zhao, Q. Lin, J. Ran, S. S. Musa, G. Yang, W. Wang, Y. Lou, D. Gao, L. Yang, D. He, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-ncov) in china, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. *International Journal of Infectious Diseases*, 92:214–217, 2020.

-
- [57] F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, J. Xiang, Y. Wang, B. Song, X. Gu, et al. Clinical course and risk factors for mortality of adult inpatients with covid-19 in wuhan, china: a retrospective cohort study. *The Lancet*, 2020.
- [58] L. Zou, F. Ruan, M. Huang, L. Liang, H. Huang, Z. Hong, J. Yu, M. Kang, Y. Song, J. Xia, et al. Sars-cov-2 viral load in upper respiratory specimens of infected patients. *New England Journal of Medicine*, 2020.